Acasti Pharma Inc. reported unaudited earnings results for third quarter and nine months ended November 30, 2012. For the quarter, the company's revenue from sales was CAD 424,320. Loss from operating activities was CAD 1,626,137 against CAD 2,212,886 a year ago. Net loss was CAD 1,611,111 or CAD 0.02 per basic and diluted share against CAD 2,207,042 or CAD 0.03 per basic and diluted share a year ago. Net cash used in operating activities was CAD 577,210 against CAD 3,304,390 a year ago. Acquisition of intangible assets was CAD 13,083. Adjusted LBITDA was CAD 1,036,000 against CAD 1,677,000 a year ago.

For the nine months, the company's revenue from sales was CAD 675,292. Loss from operating activities was CAD 4,987,130 against CAD 4,957,872 a year ago. Net loss was CAD 4,939,557 or CAD 0.07 per basic and diluted share against CAD 4,954,327 or CAD 0.08 per basic and diluted share a year ago. Net cash used in operating activities was CAD 2,608,584 against CAD 4,351,872 a year ago. Acquisition of intangible assets was CAD 19,992. Adjusted LBITDA was CAD 2,989,000 against CAD 3,624,000 a year ago. Book value per Class A share as on November 30, 2012 was CAD 0.15 against CAD 0.19 as on November 30, 2011.